Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies
December 06, 2013 06:10 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation
of a "first in human" Phase-1 study of RP6530, a...
Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013
November 19, 2013 06:35 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for
its clinical lead, RP6530, a novel, dual Phosphoinositide-3...